Noninflammatory adjuvant improving dendritic cell priming and anti-PD-L1 efficacy

被引：0
|
作者：
Seya, Tsukasa [1 ]
Takeda, Yohei [1 ]
Matsumoto, Misako [1 ]
机构：
[1] Hokkaido Univ, Sch Med, Vaccine Immunol, Sapporo, Hokkaido, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
Immunotherapy; Vaccine;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ML10
引用
收藏
页码：551 / 551
页数：1
相关论文
共 50 条
  • [21] Metformin facilitates anti-PD-L1 efficacy through the regulation of intestinal microbiota
    Xiaopeng Zhao
    Chuang Liu
    Licheng Peng
    Hongyan Wang
    Genes & Immunity, 2024, 25 : 7 - 13
  • [22] Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
    Maohua Li
    Rongqing Zhao
    Jianxin Chen
    Wenzhi Tian
    Chenxi Xia
    Xudong Liu
    Yingzi Li
    Song Li
    Hunter Sun
    Tong Shen
    Wenlin Ren
    Le Sun
    Scientific Reports, 11
  • [23] Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
    Li, Maohua
    Zhao, Rongqing
    Chen, Jianxin
    Tian, Wenzhi
    Xia, Chenxi
    Liu, Xudong
    Li, Yingzi
    Li, Song
    Sun, Hunter
    Shen, Tong
    Ren, Wenlin
    Sun, Le
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [24] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    Naidoo, J.
    Page, D. B.
    Li, B. T.
    Connell, L. C.
    Schindler, K.
    Lacouture, M. E.
    Postow, M. A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2375 - 2391
  • [25] The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
    Tunger, Antje
    Sommer, Ulrich
    Wehner, Rebekka
    Kubasch, Anne Sophie
    Grimm, Marc-Oliver
    Bachmann, Michael Philipp
    Platzbecker, Uwe
    Bornhaeuser, Martin
    Baretton, Gustavo
    Schmitz, Marc
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (10)
  • [26] Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
    Banna, Giuseppe Luigi
    Cantale, Ornella
    Bersanelli, Melissa
    Del Re, Marzia
    Friedlaender, Alex
    Cortellini, Alessio
    Addeo, Alfredo
    ONCOLOGY REVIEWS, 2020, 14 (02) : 135 - 143
  • [27] A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer
    You, Wei
    Liu, Mei
    Miao, Ji-Dong
    Liao, Yu-Qian
    Song, Yi-Bing
    Cai, Dian-Kun
    Gao, Yang
    Peng, Hao
    JOURNAL OF CANCER, 2018, 9 (07): : 1200 - 1206
  • [28] Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in patients with metastatic cutaneous squamous cell carcinoma.
    Clingan, Philip R.
    Brungs, Daniel
    Arnold, Susan
    Coward, Jermaine
    Fourie, Samuel J.
    Harris, Dean Laurence
    Kurochkin, Andrii
    Ladwa, Rahul
    Malan, Niel
    Mant, Andrew Michael
    McGrath, Margie
    Sharma, Vinay
    Shue, Hong
    Tazbirkova, Andrea
    Oliviero, James
    Desai, Jayesh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy
    Deng, Siyu
    Hu, Qianwen
    Zhang, Heng
    Yang, Fang
    Peng, Cheng
    Huang, Chuanxin
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (05) : 900 - 908
  • [30] Investigate the mechanism and treatment efficacy of regorafenib combined with anti-PD-L1 on bladder cancer
    Pai, Kai-Jen
    Chang, Yuan
    Chiang, I-Tsang
    Hsu, Fei-Ting
    CANCER RESEARCH, 2022, 82 (12)
12345